ReShape Lifesciences (RSLS) Registration Filing summary

Company overview and business model

• Operates as an innovation-driven healthcare holding company focused on the US-India corridor, leveraging cross-border talent and market opportunities in pharmaceutical R&D, medical devices, AI, and telemedicine.

• Primary focus is on clinical-stage pharmaceutical assets targeting immune and inflammatory disorders, with a differentiated strategy using US-India cost arbitrage and drug repositioning.

• Recently completed a merger, resulting in a new corporate structure and rebranding, and divested legacy assets to focus on core healthcare innovation.

Financial performance and metrics

• Completed an asset sale for $2.25 million in cash, with adjustments based on accounts receivable and payable.

• Closed a private placement of 529,137 shares at $11.02 per share immediately after the merger.

• Increased at-the-market (ATM) offering capacity from $3.42 million to $12 million.

• As of November 3, 2025, 5,630,509 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of 610,185 shares by selling stockholders; all registration expenses are covered by the company, while selling expenses are borne by the stockholders.